In an internationally conducted clinical trial lead by Dana-Farber involving patients with recurrent ovarian cancer that is resistant to platinum therapy, a novel conjugate therapy called mirvetuximab soravtansine resulted ...
Jan 31, 2023
0
73
A combination of two next-generation immunotherapy drugs has shown promising clinical activity in treating patients with refractory metastatic colorectal cancer, a disease which has not previously responded well to immunotherapies, ...
Jan 23, 2023
0
4
The field of precision cancer medicine has become so complex that even experienced oncologists can find it challenging to decipher the results of molecular tests of tumor tissue and navigate treatment options for patients. ...
Jan 12, 2023
0
25
Even as they've revolutionized cancer treatment, drugs known as immune checkpoint inhibitors can produce a range of adverse, immune-related side effects. In a new study, scientists at Dana-Farber Cancer Institute identify, ...
Dec 16, 2022
0
104
Clonal hematopoiesis (CH) is a recently characterized condition in which the genetic mutations associated with leukemia and other blood cancers are found in the blood of individuals without cancer. This pre-cancerous state ...
Dec 13, 2022
0
8
Every year, up to 1% of patients with chronic lymphocytic leukemia (CLL), a slow-growing blood cancer, have their disease transform into a far more aggressive cancer, a form of lymphoma known as Richter's syndrome. For the ...
Dec 12, 2022
0
61
A CAR-T-cell therapy known as axicabtagene ciloleucel (axi-cel) is safe and shows encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, Dana-Farber Cancer Institute ...
Dec 11, 2022
0
38
A three-drug combination that sent chronic lymphocytic leukemia (CLL) into deep remission in a broad group of patients in a clinical trial is highly effective in patients with high-risk forms of the disease, a new, phase ...
Dec 10, 2022
0
45
Scientists at Dana-Farber Cancer Institute have developed a drug that potently neutralizes SARS-CoV-2, the COVID-19 coronavirus, and is equally effective against the Omicron variant and every other tested variant. The drug ...
Dec 7, 2022
0
540
For many patients with a condition that often precedes multiple myeloma, early treatment can slow or delay the progression to myeloma. In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes ...
Nov 14, 2022
0
263
